Sign Up for a Free Account
  • Updated 04.09.2023
  • Released 03.11.1998
  • Expires For CME 04.09.2026

Bell palsy



The clinical article reviews the clinical presentation, diagnosis, pathogenesis, and management of Bell palsy. Bell palsy is an acute, usually unilateral mononeuropathy of the seventh cranial nerve. The disorder is presumed to be inflammatory and associated with one of several different viral etiologies, usually herpes simplex virus-1. The disorder is usually self-limiting, with up to 90% of affected subjects showing full recovery. Recovery occurs within 6 months, and most will improve within 3 weeks of onset of the disorder. The differential diagnosis is outlined in this clinical article, and specific tests may be indicated for certain patients depending on the clinical evaluation. Early treatment with steroids is recommended. Several large randomized studies clearly show that prednisone (prednisolone), given within 48 hours of onset of the palsy, improves recovery rate and promotes early recovery in affected patients. Combination therapy with antivirals is not recommended based on current clinical trial and meta-analysis data. In addition, supportive care and eye care are critical.

Historical note and terminology

Bell palsy was named for Sir Charles Bell (1774-1842), a British neurologist, who in 1821 described the condition and demonstrated that there was a separation of motor and sensory innervation in the face. Similar descriptions of the disorder were, however, previously published by Nikolaus A Friedreich (1825-1882) in 1798 and Richard Powell in 1813.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125